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Objectives. This study was performed to assess the influence 
and interdependence of immunologic and nonimmnnologic risk 
factors in the development of cardiac allograft vasculopathy. 
Another primary objective was to establish a clinically useful 
model for risk assessment of cardiac allograft vasculopathy that 
would facilitate identifying those heart transplant recipients likely 
to have severe intimal proliferation and thereby at greatest risk 
for adverse clinical events. 
Background. To our knowledge, no comprehensive intravascu- 
lar ultrasound study has assessed the relative influences of both 
nonimmunologic and immunologic factors in the development of 
cardiac allograft vascnlopathy, currently the major limitation to 
long-term cardiac allograft survival. 
Methods. Using a computer-assisted model of stepwise logistic 
regression, immunologic and nonimmunologic risk factors were 
evaluated to help identify the development of severe intimal 
thickening in 101 subjects who underwent intravascular ultra- 
sound. Prospective validation of the findings was performed in a 
separate consecutive cohort of 37 heart transplant recipients, and 
the accuracy of this model to predict a relative risk >1 for the 
development of severe intimal hyperplasia was assessed. 
Results. Significant independent predictors of severe intimal 
hyperplasia in this model included a donor age >35 years, a 
first-year mean biopsy score > 1 (a measure not only of severity of 
rejection, but also of frequency of insidious rejection) and hyper- 
triglyceridemia t two incremental levels of risk (150 to 250 mg/dl 
[1.70 to 2.83 mmol/liter] and >250 mg/di [2.83 retool/liter]). 
Based on the absence (0) or presence (1) of these factors, 12 
individual categories of risk were ascertained with increasing 
relative risks and predicted probabilities for severe intimal hy- 
perplasia. Prospective validation of this model revealed a sensi- 
tivity and specificity of 70% and 90%, respectively, and the positive 
and negative predictive values were 85% and 80%, respectively. 
Additionally, subjects with severe intimal thickening had a four- 
fold higher cardiac event rate than those without severe intimal 
proliferation on intravascular ultrasound. 
Conclusions. This study establishes a clinically useful predic- 
tive model that can be applied to individual heart transplant 
recipients to assess their risk for developing significant cardiac 
allograft vasculopathy and, thus, aids in the identification of 
patients at risk for cardiac events in whom closer surveillance and 
risk factor modification may be warranted. 
(JAm CoU Cardio11995;26:1537-44) 
The long-term success of heart ransplantation continues to be 
jeopardized by the development of cardiac allograft vasculopa- 
thy, an unusually accelerated form of coronary artery disease 
responsible for the majority of allograft losses in patients who 
survive >1 year (1). This disease ntity is characterized by 
rapidly progressive ascular myointimal hyperplasia that even- 
tually leads to coronary lumen compromise and the subsequent 
catastrophic manifestations of myocardial infarction, allograft 
dysfunction and sudden death (2,3). 
Intravascular ultrasound has been used to identify the 
presence of myointimal proliferation in heart transplant re- 
cipients and has been found to do so in an accurate and 
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reproducible manner. This imaging modality has also been 
found (4,6) to complement coronary angiography in the mor- 
phologic assessment of cardiac allograft vasculopathy because 
it can identify significant intimal thickening even in the pres- 
ence of normal findings on the coronary angiogram. Further- 
more, intravascular ultrasound not only plays a useful role in 
the morphologic characterization f cardiac allograft vascu- 
lopathy, but it also allows prediction of clinical outcome in 
heart ransplant recipients with significant intimal hyperplasia. 
A recent study by Mehra et al. (7) demonstrated that in heart 
transplant recipients, the presence of severe intimal hyperpla- 
sia is associated with a higher isk of cardiac events than the 
presence of mild or moderate intimal proliferation, even in the 
presence of normal angiographic results. 
The development of myointimal hyperplasia n the graft 
vascular bed requires loss of the protective integrity of endo- 
thelium (8). This loss of vasoprotection may arise from the 
concerted actions of several nonimmunologic risk factors, 
operating within a milieu conditioned by adverse host immu- 
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nologic responses to the foreign cardiac allograft (9,10). This 
hypothesis has fueled an intense search for the link between 
several nonimmunologic risk factors, such as abnormal lipid 
characteristics and obesity (11-13), diabetes mellitus, donor 
and recipient age and gender (14-16), cold ischemic time and 
cytomegalovirus infection (17,18) as well as immunologic 
factors, including cellular or humoral allograft rejection, his- 
tocompatibility (19-21) and elevated soluble interleukin-2 
receptor levels (22), with the subsequent development of 
cardiac allograft vasculopathy. Unfortunately, these studies 
have been limited in examining the relative magnitudes of risk 
arising from the presence of such risk factors. Although these 
investigations are of importance in enhancing our understand- 
ing of the pathophysiology of cardiac allograft vasculopathy, 
they do not provide nough information to enable the clinician 
to assess an individual heart transplant recipient's risk for 
cardiac allografl vasculopathy. 
The purpose of the present investigation was 1) to assess 
the influence and interdependence of immunologic and non- 
immunologic risk factors in the development of severe intimal 
proliferation; 2) to establish a clinically useful model for risk 
assessment of cardiac allograft vasculopathy; and 3) to pro- 
spectively validate the accuracy of this predictive model in 
identifying those heart transplant recipients likely to have 
severe intimal proliferation and thus be at greatest risk for 
adverse clinical events. 
Methods  
Patients. Using intravascular ultrasound, we studied a co- 
hort of 138 consecutive and different heart transplant recipi- 
ents at the time of routine annual coronary angiography 
between January 1991 and June 1994. All recipients received 
identical triple-drug immunosuppressive therapy (cyclospo- 
rine, prednisone and azathioprine) and were free of acute 
rejection and infection at the time of the ultrasound study. 
Patients were excluded from the study if they were ineligible 
for cardiac atheterization, died during the initial hospital stay 
or refused to give consent. Written informed consent was 
obtained from all patients, and the study was approved by the 
institutional review board. 
Nonimmunologic risk factors. Fasting lipid profiles (serum 
triglyceride, total cholesterol, ow density lipoprotein [LDL] 
and high density lipoprotein [HDL] levels) were assessed in all 
patients at the time of ultrasound examination. Serum triglyc- 
eride levels were evaluated after an overnight 10-h fast and 
were measured enzymatically using the glycerol phosphate 
oxidase method (Boehringer Mannheim). Obesity assessment 
(percent weight gain, body mass index), hypertension (defined 
according to the Report of the Fifth Joint National Committee 
on Detection, Evaluation, and Treatment of High Blood 
Pressure [JNC V] criteria) (23), diabetes mellitus, donor age 
and gender, ischemic time, time since transplantation and 
cytomegalovirus infection (defined as a clinical syndrome in 
association with either new seroconversion, positive blood 
cultures or evidence of tissue invasion) requiring therapeutic 
intervention with intravenous gancyclovir were also assessed in
all heart transplant recipients. 
Immunologic risk factors including allograft rejection. 
Rejection surveillance during the first year consisted of weekly 
endomyocardial biopsies for the first month after transplanta- 
tion, biweekly until the third month, monthly until the sixth 
month and bimonthly thereafter until completion of the first 
year. Thus, the routine protocol mandates the performance of
14 biopsies during the first year. All biopsies were graded on 
the basis of the standard biopsy grading scheme developed by 
the International Society for Heart and Lung Transplantation 
(ISHLT) (24). The criteria for treatment of cellular rejection 
included the finding of a 3A or higher biopsy grade. If 
treatment was initiated for a lower biopsy grade, it was done 
only in the presence of hemodynamic compromise as evi- 
denced by one or more of the following: 20% decrease in 
ventricular ejection fraction; increase in pulmonary capillary 
wedge pressure ->25%; and 25% decrease in cardiac index or 
an absolute value <2.0 liters/rain per m 2. The protocol for 
treatment of acute cellular rejection in the absence of hemo- 
dynamic ompromise involved 2 to 5 mg/kg body weight per 
day of oral corticosteroids or intravenous equivalent for 3 days, 
then a 5-day taper to baseline. In the event of hemodynamic 
compromise, 500 to 1,000 mg of intravenous teroids was 
administered for 3 days, followed by rapid return to baseline. 
Antilymphocytic antibodies (OKT3) were given only for grade 
3B or 4 rejection with hemodynamic compromise. Only two 
patients in the present study cohort required use of antilym- 
phocytic antibodies (OKT3) for reversal of acute rejection. All 
episodes of treated rejection mandated the performance of a 
follow-up biopsy in 1 week for documentation f resolution or 
evidence for regression to a lower rejection grade. Thus, 
episodes of treated cellular ejection were analyzed in all study 
patients. 
In addition, a first-year mean biopsy rejection score was 
determined for all patients. This score was adapted from the 
standardized ISHLT criteria (24), and individual scores were 
assigned to each defined biopsy grade as follows: ISHLT grade 
0 = 0; grade IA = 1; grade IB = 2; grade 2 = 3; grade 3A = 
4; grade 3B = 5; and grade 4 = 6. The mean biopsy score was 
computed as the average of all biopsy scores during the first 
year after transplantation. 
In addition, episodes of vascular ejection and the number 
of human leukocyte antigen (HLA)-A, -B or -DR matches 
between the donor and recipient were assessed in all patients. 
Acute vascular rejection was defined by the presence of 
hemodynamic compromise, along with histologic evidence of 
endothelial cell activation and a positive immunofluorescence 
on biopsy. More important, detailed immunosuppression reg- 
imens were assessed in all patients by calculating the cumula- 
tive prednisone dose (total amount of intravenous and oral 
prednisone consumed [g]), average daily prednisone dose 
(mg/kg per day), cumulative cyclosporine dose (total amount 
of intravenous and oral cyclosporine consumed [kg]), mean 
cyclosporine dose (mg/kg per day) and mean cyclosporine 
levels (pg/ml) and cumulative (total amount of oral azathio- 
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prine consumed [kg]) mean azathioprine (mg/kg per day). Use 
of cytolytic therapy (OKT3 or antithymocyte globulin) and 
methotrexate was also assessed for each study patient. 
Intravascular ultrasound. Coronary ultrasound procedure. 
Coronary ultrasound was performed as previously reported 
(5,6). After administration f 200 tzg of intracoronary nitro- 
glycerin, the ultrasound catheter was positioned in the distal 
segment of the target vessel over a 0.014-in. (0.036-cm) guide 
wire. The target vessel was selected by the presence of at least 
three easily definable and reproducible branch points to assist 
in the accurate and serial assessment of three regions of 
interest. The guide wire was removed, and the ultrasound 
catheter was advanced to the distal end of the ultrasound 
sheath under fluoroscopic guidance. The drive module was 
then engaged, and continuous images of the coronary artery 
were obtained as the ultrasound transducer was slowly with- 
drawn. Additionally, fluoroscopic pictures and audio annota- 
tions were used to ensure the correct localization of the artery 
segment for subsequent off-line analysis. Guiding catheter 
pressure, ST segment changes and cardiac rhythm were con- 
tinuously monitored uring the procedure. After ultrasound 
images were obtained, both the transducer and sheath were 
removed, and a final angiogram was obtained to confirm the 
patency of the coronary vessel. No complications were encoun- 
tered except for coronary artery vasospasm, readily reversed by 
intracoronary infusion of nitrates or verapamil. 
Coronary ultrasound assessment. Intravascular ultrasound 
measurements were performed by an investigator who had no 
knowledge of the previous assessment of risk factors. Three 
coronary sites per vessel (proximal, middle and distal), for a 
total of 414 coronary artery segments, were evaluated. The left 
anterior descending coronary artery was examined in 112 
patients, circumflex artery in 8 and right coronary artery in the 
remaining 18 subjects. Maximal intimal thickness and intimal 
area were obtained by tracing the lumen vessel wall interface 
and the external border of the intimal ayer. Intimal index was 
calculated as the ratio of intimal area to total vessel area. The 
intraobserver (4.1%) and interobserver (5.4%) variability was 
assessed as previously reported (14) and demonstrated good 
test reproducibility. Lesions were further assessed with regard 
to plaque location, morphology and eccentricity. The predom- 
inant morphologic haracteristics of the vessels studied re- 
vealed diffuse and concentric lesions in 86%, whereas only 
14% of vessels tudied revealed proximal, focal and eccentric 
lesions. Severe intimal thickness was defined on the basis of the 
scheme previously described by St. Goar et al. (4), wherein 
severe intimal thickening isrepresented by>0.5 mm of intimal 
proliferation i volving >180 ° of the vessel circumference or 
any intimal layer >1.0 mm in any one area of the vessel 
circumference. All values less than this threshold were deemed 
to represent "nonsevere" intimal proliferation. This threshold 
of severity denotes the "unequivocal" presence of intimal 
thickening and is beyond the 98th percentile of any published 
"normal" values. Moreover, we previously demonstrated (7) 
that severe intimal proliferation by intravascular ultrasound is
predictive of cardiac events, even in the absence of anglo- 
graphic abnormalities. 
Cardiac events. Cardiac events analyzed included sudden 
cardiac death, myocardial infarction and persistent allograft 
dysfunction, despite augmented immunosuppression, as well as 
the need for coronary revascularization bypercutaneous tech- 
niques (angioplasty, atherectomy, stent implantation) orcoro- 
nary artery bypass urgery. 
Statistical methods. Statistical analysis was performed us- 
ing the BMDP 386 Dynamic statistical software module for 
stepwise logistic regression (BMDP-LR). Logistic regression 
analysis works in a similar manner to linear regression. Both 
methods result in an equation describing a curve of best fit. 
However, a logit transform is applied so that predicted prob- 
abilities from the equation will not exceed the boundaries of 0 
and 1. The resulting curve is sigmoidal, with asymptotes at 0 
and 1, rather than a line. A goodness-of-fit test is used to 
determine whether the model describes the data well rather 
than the correlation coefficient in linear regression. The step- 
wise fitting of the model excludes variables with coefficients not 
statistically different from zero. 
The starting set of the previously described immunologic 
and nonimmunologic variables was selected, and the influence 
of these variables on the development of severe intimal 
hyperplasia by intravascular ultrasound was then assessed. The 
variables for entry into or removal from the computer-assisted 
model were p values of the maximal likelihood ratio of 0.10 
and 0.15, respectively. The improvement chi-square (null hy- 
pothesis: "there is no improvement") and goodness-of-fit 
chi-square tests (null hypothesis: "the model fits the data") 
were considered significant at p < 0.10 and p > 0.20, respec- 
tively. Interaction terms were not allowed to remain in the 
model unless the component main effects were considered 
significant. 
Normally distributed ata are reported as mean value _+ 
SD. Differences between categoric variables were assessed 
using the chi-square or the Fisher exact test. An unpaired 
Student t test was used to define differences between continu- 
ous variables in subgroups. Kaplan-Meier actuarial analysis 
was used to assess event-free survival for the study cohort. 
Resu l ts  
Clinical characteristics. The present study group included 
138 consecutive and different heart ransplant recipients (116 
men, 22 women; mean [_+SD] age 50 _+ 11 years, range 22 to 
68) who were studied a mean of 2.3 _+ 1.4 years after 
transplantation (range 1 to 4). The first 101 consecutive 
patients formed the "derivation" cohort and were utilized to 
determine the predictive variables that could assess asubject's 
risk for having severe intimal proliferation, whereas the next 37 
consecutive patients in the "validation" cohort were prospec- 
tively utilized to assess the clinical accuracy of these predictive 
factors. Table 1 presents comparative patient characteristics of 
the derivation and validation cohorts with regard to nonimmu- 
nologic (cold ischemic time, lipid characteristics, weight gain, 
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Table 1. Patient Characteristics 
Derivation Validation 
Cohort Cohort 
(n = 101) (n = 37) 
Age (yr) 50 _~ 10.5 52 +- 12 
Gender (M/F) 86/15 30/7 
Time after transplantation (yr) 2.3 +_ 1.4 2.2 +_ 1.7 
Intimal thickness (ram) 0.49 ± 0.37 0.50 ± 0.38 
Intimal index 0.22 _+ 0.16 0.18 _+ 0.11 
Ischemic time (rain) 181 _+ 58 194 _+ 66 
Total cholesterol (mg/dl) 239 ± 62 249 +_ 69 
LDL cholesterol (mg/dl) 151 + 50 143 - 35 
HDL cholesterol (mg/dl) 46 ± 15 50 ± 12 
Triglycerides (mg/dl) 198 _+ 97 231 ± 164 
Weight gain (%) 12.3 +_ ll 11.9 +_ 9 
Donor age (yr) 25 ± 9 27 _+ 11 
Donor gender (M/F) 67/34 21/16 
Cytomegalovirus nfections (%) 16 14 
Diabetes mellitus (%) 36 32 
HLA matches 0.8 _+ 0.9 0.9 ± 0.6 
Treated cellular rejections (%) 39 33 
Biopsy rejection score 0.99 ± 0.39 0.94 _+ 0.40 
Data presented are mean value _+ SD or number or percent of patients. F = 
female; HDL = high density lipoprotein; HLA = human leukocyte antigen; 
LDL = low density lipoprotein; M = male. 
cytomegalovirus infections, diabetes mellitus, donor age, do- 
nor gender) and immunologic (episodes of allograft rejection, 
HLA matches, mean first-year biopsy rejection score) risk 
factors. Thus, the derivation and validation groups were similar 
with regard to the prevalence of all risk factors tudied. 
Statistical model. Of all immunologic and nonimmuno- 
logic variables assembled, the statistical method of stepwise 
logistic regression screened out those that did not meet 
statistical significance. This method allowed for evaluation and 
control of confounding or interacting variables. In the final 
model, donor age >35 years, serum triglyceride l vels of 150 to 
250 mg/dl (1.70 to 2.83 mmolAiter) (level 1) and those >250 
mg/dl (2.83 mmol/liter) (level 2), as well .as a first-year mean 
biopsy rejection score emerged as significant independent 
predictors of severe intimal thickening. Variables that were not 
found to be significant included recipient age and gender, 
donor gender, cold ischemic time, serum cholesterol, LDL 
cholesterol, HDL cholesterol, weight gain after transplant, 
time elapsed since transplantation, histocompatibility, acute 
vascular ejection and cytomegalovirus infection. 
Donor age and hyperlipidemia. Donor age was grouped 
around the cutpoint of 35 years of age in accordance with the 
central tendency of our data and previous findings (25). Serum 
triglyceride levels were classified into three groups: 1) <150 
rag/all (1.70 mmol/liter); 2) 150 to 250 mg/dl (1.70 to 2.83 
mmol/liter) (level 1); and 3) >250 mg/dl (2.83 mmol/liter) 
(level 2). These cutpoints were based on the findings of the 
Framingham Heart Study (26), which established an indepen- 
dent and incremental risk for the development of coronary 
artery disease around the two distinct levels of 150 to 250 
mg/dl. 
Cellular allograft rejection and mean biopsy score. There 
was no relation between episodes of treated cellular allograft 
rejection and the presence of severe intimal proliferation. 
Conversely, the first-year mean biopsy score, which approxi- 
mated a ganssian distribution with a median around 1, was 
found to be a significant independent predictor of severe 
intimal hyperplasia. To further examine the clinical value of 
the mean biopsy score, we assessed the relation of this score 
with the number of biopsy procedures, as well as with the 
number of treated episodes of rejection. Heart transplant 
recipients with a mean biopsy score of >1 had a greater 
number of biopsies performed than patients with a biopsy 
score <1 (16 ± 4.8 vs. 13 _+ 2.6, p = 0.02). In addition, a 
positive correlation between the number of biopsies performed 
and mean biopsy score (r = 0.36, p = 0.002) was found, 
suggesting that most additional biopsies were performed in the 
presence of higher rejection grades. Furthermore, patients 
with treated episodes of rejection had higher mean biopsy 
rejection scores than patients without episodes of rejection 
(1.22 _+ 0.37 vs. 0.89 +_ 0.39, p = 0.003). When episodes of 
cellular rejection were treated with augmented immunosup- 
pression, the mean number of additional biopsies performed in 
the ensuing 4 weeks was 1.3 + 0.4. 
Immunosuppression. There were no significant differences 
between immunosuppression regimens in patients with severe 
and nonsevere intimal thickness. Average daily cyclosporine 
dose (3.8 vs. 3.9 mg/kg per day, p = 0.9), mean cyclosporine 
blood levels (168 vs. 164 pg/ml, p -- 0.4), cumulative cyclospo- 
rine dose (0.37 _+ 0.22 vs. 0.45 _+ 0.28 kg, p = 0.13), cumulative 
prednisone consumption (12.0 vs. 13.8 g, p = 0.14), average 
prednisone dose (0.11 vs. 0.10 mg/kg per day, p -- 0.3) and 
cumulative azathioprine (0.11 _+ 0.08 vs. 0.16 +_ 0.12 kg, p -- 
0.02) did not differ significantly between patients with nonse- 
vere and severe intimal proliferation, respectively. Linear 
regression analysis of the interaction of cumulative prednisone 
close used for treatment of acute rejection episodes with the 
first-year mean biopsy rejection score revealed no significant 
correlation (r -- 0.11, p = 0.3). 
Analysis of predictive variables. On the basis of the results 
of statistical analysis, the significant variables that emerged as 
independent predictors were donor age >35 years; serum 
triglyceride levels 150 to 250 mg/dl (1.70 to 2.83 mmol/liter) 
(level 1) and >250 mg/dl (2.83 mmol/liter) (level 2); and a 
first-year mean biopsy rejection score >1. The final model can 
be shown as an equation of predicted log odds as follows: 
Log odds = - 2.8 + 3.5 (Donor age > 35 years) 
+ 1.5 (150 to 250 mg/dl) + 2.1 (Triglycerides > 250 mg/dl) 
+ 1 (First-year mean biopsy score > 1). 
This equation emphasizes the relative contributions of these 
significant variables in the development of severe intimal 
thickening. The predicted log odds can then be converted to 
relative risk and predicted probability (~), both reflecting the 
chance that a given patient will have severe intimal hyperpla- 
sia, by the formula: 
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Figure 1. Predicted probability for severe intimal hyperplasia by 
individual patient risk categories. Categories 1 to 5 define relative risk 
(RR) -1; whereas categories 6 to 12 define RR >1 for cardiac 
allograft recipients with versus without the adverse risk profile (con- 
version factor for serum triglyceride levels from mg/dl to mmol/liter is 
0.0113). 
Relativerisk=e (~/l-f,) and (1 b) = e(~'l-O)/l+e(O/1-o) 
Based on the absence (coded as 0) or presence (coded as 1) of 
these predictive factors, 12 possible categories of patient 
profiles with increasing probabilities for having severe intimal 
proliferation can be established and are delineated inFigure 1. 
Furthermore, relative risks for each patient category can also 
be calculated and are shown in Figure 2. 
Clinical use of predictive variables. The prediction of 
probability of having severe intimal thickening in any given 
patient requires the categorization f individual patients into 
one of the 12 possible groups (Fig. 1 and 2). Thus, if the 
Figure 2. Relative risk (RR) for individual patient categories for 
development of severe intimal hyperplasia classified by risk factor 
profile into 12 patient categories. Categories 1 to 5 denote RR <1, 
whereas categories 6 to 12 denote RR >1. 
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Figure 3. Actuarial probability ofcardiac event-free survival for severe 
versus nonsevere intimal proliferation (IP). 
clinician wishes to assess the risk for development of severe 
intimal hyperplasia in a 52oyear-old heart ransplant recipient 
of a 16-year-old allograft donor with a serum triglyceride l vel 
of 112 mg/dl (1.27 mmol/liter) and a first-year mean biopsy 
rejection score of 0.94, this particular patient would fit into 
category 1(0, 0, 0, 0) and have a predicted probability of 0.06 
for developing severe intimal hyperplasia. Conversely, a pa- 
tient with a 47-year-old cardiac donor allograft, a serum 
triglyceride level of 278 mg/dl (3.14 mmol/liter) and a biopsy 
rejection score of 1.3 would be in category 12 (1, 0, 1, 1) and 
have a predicted probability of 0.98 for developing significant 
intimal thickness. 
Prospective validation. A cohort of 37 consecutive heart 
transplant recipients was used to define prospectively the 
accuracy of this model for predicting a relative risk >1 of 
having severe intimal hyperplasia. Using the predictive model, 
Categories 1 to 5 were defined to denote a relative risk -<1, 
whereas Categories 6 to 12 were associated with a relative risk 
>1 (Fig. 1). Sixteen patients were found to have severe intimal 
hyperplasia, whereas the remaining 21 patients had minimal or 
mild intimal thickening. Of this group, use of the predictive 
model accurately classified 19 to 21 patients as having a relative 
risk of -<1, and 11 of 16 patients were correctly classified with 
a relative risk >1. Thus, the sensitivity and specificity were 
70% and 90%, respectively, whereas the positive and negative 
predictive values were 85% and 80%, respectively. The overall 
accuracy of this model was 81%. 
Morphologic characterization and cardiac event analysis. 
A total of 25 cardiac events occurred in the entire study group. 
Of these, there were 14 sudden deaths, 6 myocardial infarc- 
tions and persistent allograft dysfunction despite augmented 
immunosuppression a d 5 coronary revascularizations (1 an- 
gioplasty, 2 directional atherectomies, 2 stent implantations), 
yielding an event rate of 7.8%/patient per year. In addition, 
patients with severe intimal proliferation were three times 
more likely to have a cardiac event han patients with nonse- 
vere intimal thickening (30% vs. 10.2%, p = 0.009). Actuarial 
probability of event-free survival in heart ransplant recipients 
with severe intimal proliferation compared with nonsevere 
intimal thickening is depicted in Figure 3. The morphologic 
assessment ofthe distribution of intimal proliferation revealed 
that 86% of the lesions were concentric (>180 ° ) and 81% 
diffuse, whereas 14% were eccentric and 19% focal. Because 
donor age >35 years emerged as one of the most important 
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Figure 4. Cardiac death rates in subjects with severe intimal prolifer- 
ation and a donor age >35 years versus those with donor age -<35 
years. Recipients of a donor allograft >35 years old have a fourfold 
higher incidence of cardiac death. 
predictive factors for having severe intimal proliferation, we 
also examined the prevalence of cardiac events in the group of 
patients with severe intimal proliferation and donor age >35 
years compared with patients with a donor age -<35 years. The 
incidence of cardiac death was four times higher in the patients 
with severe intimal proliferation and donor age >35 years than 
in those with a donor age -<35 years (27% vs. 6%, p < 0.005) 
(Fig. 4). Similar differences were evident in the patients with 
advanced onor age when all cardiac events were assessed 
(42% vs. 14%, p < 0.001). Of particular note is the finding that 
88% of the lesions in this high donor age group were diffuse 
and concentric, whereas only 12% demonstrated focal and 
eccentric intimal thickening. 
Angiographic data in the patient cohort with severe intimal 
proliferation revealed that 23% of the subjects demonstrated 
normal angiographic findings despite intravascular ultrasound 
evidence of disease. More significantly, 32% of the study 
cohort that had a cardiac event had no antecedent anglo- 
graphic abnormality despite demonstration of severe intimal 
proliferation by intravascular ultrasound. 
Discussion 
Predictive model. According to our risk assessment model, 
the results of the present intravascular ultrasound study indi- 
cate that the presence of donor age >35 years, hypertriglyc- 
eridemia nd a high first-year mean biopsy rejection score are 
independently and significantly associated with the risk of 
having severe intimal thickening. This predictive model not 
only elucidates the relation of these three immunologic and 
nonimmunologic risk factors among each other, but also allows 
identification of heart transplant recipients at risk for the 
deleterious consequences of cardiac allograft vasculopathy. 
Moreover, prospective validation of this model determined 
that use of these predictive factors provides a highly accurate 
assessment of risk for having severe intimal proliferation, with 
positive and negative predictive values of 85% and 80%, 
respectively. 
Donor age and cardiac aUograft vasculopathy. The find- 
ings of the present study are consistent with the notion that an 
interplay among an aged allograft, hyperlipidemia and insidi- 
ous immunologic damage from allograft rejection may be 
associated with the development of significant intimal hyper- 
plasia (25). A critical assessment of the relative influences of 
these risk factors within the model suggests that advanced 
donor age accounts for one of the highest risks for developing 
severe intimal hyperplasia. Analysis of donor age in the context 
of the predictive model suggests that if a heart transplant 
recipient were to have a donor age >35 years as the sole risk 
factor, with normal serum lipid levels and a first-year biopsy 
rejection score <1, that patient would have a predicted 
probability of 0.69 and a relative risk of 2.23 for having severe 
intimal thickening. In addition, the presence of donor age >35 
years confers a fourfold higher risk of cardiac death than 
cardiac events in recipients of younger (<35 years) allografts. 
Recent studies that have evaluated the influence of donor age 
in the development of cardiac allograft vasculopathy have 
yielded similar results. Tuzcu et al. (27) examined 22 heart 
transplant recipients serially at baseline and 1 year after 
transplantation using intravascular ultrasound and demon- 
strated that patients with a donor age >35 years developed the 
greatest increase in intimal proliferation. Another recent in- 
vestigation by Gao et al. (28) revealed that recipients of donor 
hearts with advanced onor age (>40 years) were less likely to 
be free from development of cardiac allograft vasculopathy 
than those who received younger allografts (<40 years). The 
reasons for this influence of donor age on the development of
intimal hyperplasia remain speculative. However, it is likely 
that the older allograft may be more susceptible toendothelial 
damage resulting from the host-graft immunologic and non- 
immunologic interaction. 
Hyperlipidemia and cardiac allograft vasculopathy. The 
role of hyperlipidemia and its influence on cardiac allograft 
vasculopathy has been a matter of intense scrutiny. Several 
studies (11,29-32) have uniformly demonstrated that hyper- 
cholesterolemia, ncreased LDL cholesterol and hypertriglyc- 
eridemia begin to develop 1 year after transplantation. Al- 
though the exact cause of posttransplantation hyperlipidemia 
remains uncertain, obesity and immunosuppressive agents are 
thought o play an integral role in its development. I  has been 
demonstrated (33,34) that cyclosporine decreases lipoprotein 
lipase activity and inhibits prednisone clearance by its interac- 
tion with the hepatic ytochrome P-450 system. Furthermore, 
prednisonc may increase hepatic apolipoprotein B production 
(35). These effects result in impaired very low density lipopro- 
tein (VLDL) and LDL clearance and lead to hypercholester- 
olemia and hypertriglyceridemia. An intriguing new concept 
relates to the role of insulin resistance in the development of
hypertriglyceridemia and its consequent propagation of car- 
diac allograft vasculopathy. However, confirmation of this 
concept awaits further scrutiny. The findings of the present 
study not only suggest the predictive value of elevated serum 
triglyceride levels in the development of severe intimal hyper- 
plasia, but also suggest that this risk is incremental and 
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increases exponentially with the degree of hypertriglyceri- 
demia. The mechanisms underlying the influence of elevated 
triglyceride levels on vascular intimal thickening in heart 
transplant recipients may be diverse and can be related either 
directly to the atherogenic potential of VLDL particles or may 
result from the metabolic onsequences of hypertriglyceri- 
demia that include an increase in small, dense LDL particles 
and low levels of HDL cholesterol (36). 
Cellular rejection and cardiac allograft vasculopathy. One 
issue that has remained a matter of controversy is the role of 
cellular allograft rejection in the development of cardiac 
allograft vasculopathy. Although several studies exist that 
dispute an association between the two, some studies have 
linked acute cellular allograft rejection with cardiac allograft 
vasculopathy (1,19). Uretsky et al. (1) demonstrated that there 
is an association between the occurrence of two or more major 
rejection episodes and the prevalence and severity of cardiac 
allograft vasculopathy, thus suggesting that multiple immuno- 
logic events may be necessary for the development of cardiac 
allograft vasculopathy. In a separate study that analyzed the 
association between cardiac allograft vasculopathy and both 
frequency and histologic severity of rejection, Schiitz et al. (37) 
demonstrated higher rejection scores in patients with than 
without manifestations of cardiac allograft vasculopathy. In a 
study of failed human allografts, Winters et al. (12) suggested 
that even minimal endomyocardial rejection may contribute 
insidiously to the development of cardiac allograft vasculopa- 
thy. These varied observations suggest hat not only is the 
number of episodes of rejection important, but the degree of 
histologic severity, particularly low grade insidious cellular 
rejection, may also play a crucial role in the development of
cardiac allograft vasculopathy. Although episodes of treated 
cellular rejection were not an independent risk factor for 
severe intimal proliferation in our investigation, the mean 
first-year biopsy rejection score emerged as a significant risk 
factor. The clinical value of the average biopsy rejection score 
lies in its ability to account not only for the frequency of high 
grade rejection occurrence, but also the risk conferred by lower 
grades of rejection severity that would otherwise not be 
construed to represent clinical rejection. Furthermore, the 
presence of a mean first-year biopsy rejection score >1, in 
conjunction with a donor age >35 years and the presence of 
hypertriglyceridemia, adds to the risk for development of 
severe intimal thickening. As our model demonstrates, when a 
biopsy score >1 accompanies a donor age >35 years as a risk 
factor, the predicted probability for severe intimal thickness 
increases from 0.69 to 0.86 in any individual heart transplant 
recipient, and the addition of hypertriglyceridemia enhances 
this predicted probability to >0.90. 
Clinical significance. The clinical ramifications of the 
present study lie in the recognition of the heart transplant 
recipient most likely to suffer the devastating consequences of 
cardiac allograft vasculopathy. Not only does our predictive 
model allow close scrutiny of the individual influences of donor 
age, hypertriglyceridemia and allograft rejection as well as 
their interrelation i  the development of severe intimal thick- 
ening in an individual heart ransplant recipient, but it does so 
with an overall accuracy of 81%. Indeed, the group of subjects 
identified by this model are also those most likely to suffer a 
cardiac event, as was evident by the threefold higher cardiac 
event rate in the heart ransplant recipients with severe intimal 
proliferation. Thus, it may seem reasonable to suggest hat in 
this highly select group, closer monitoring for rejection and 
modification of hypertriglyceridemia by control of predispos- 
ing factors may be warranted. 
Study limitations. Certain potential limitations of this 
study merit emphasis. 
1. An important issue relates to the lack of baseline 
intravascular ultrasound studies that would have allowed ex- 
clusion of donor-transmitted disease as a potential confound- 
ing variable. A recent intravascular ultrasound investigation of 
advanced onor age allografts (38) has alluded to the signifi- 
cant transmission of "occult" coronary disease at the time of 
transplantation. This finding is particularly important o our 
study because advanced onor age was a very potent risk factor 
for severe intimal proliferation. Evidence to suggest that these 
study results are less likely to have arisen solely due to this 
phenomenon are as follows: a) The prevalence of severe 
intimal proliferation in our advanced onor age group (>35 
years) is 94%, which is higher than that of donor-transmitted 
disease; b) the disease distribution was more diffuse and 
concentric, as opposed to the predominance ofproximal, focal 
and eccentric intimal thickening in donor-transmitted disease; 
c) more importantly, heart transplant recipients with the 
higher donor age (>35 years) were four times more likely to 
suffer a cardiac death or other cardiac-related vent as a result 
of cardiac allograft vasculopathy. These results emphasize that 
the relation of advanced onor age with severe intimal prolif- 
eration is unlikely to have resulted from simply the effect of 
disease transmitted at the time of transplantation. Further- 
more, other recent investigations (27,28) have also suggested 
an important role for advanced onor age in determining 
progression of intimal proliferation. 
2. The possible beneficial influence of pharmacologic 
agents, such as the calcium entry blocking agent diltiazem (39), 
as well as lipid-lowering therapy on the development of cardiac 
aUograft vasculopathy is a potential limitation. However, only 11 
heart ransplant recipients were receiving diltiazem and 19 lipid- 
lowering medications during the study period and are therefore 
unlikely to have affected the results ignificantly. 
3. Another important limitation relates to our use of a 
first-year mean biopsy rejection score as a marker for contin- 
ued immunologic stimulation of the transplanted allograft. 
Although this system is useful in assessing the graded severity, 
frequency and influence of insidious immunologic activation, it 
does not assess the relation between episodes of rejection 
occurring after the first year, albeit infrequent, and the devel- 
opment of cardiac allograft vasculopathy. 
4. A possible limitation relates to the three-site image 
analysis intravascular imaging protocol used in this study. 
More recently, morphometric analysis of intravascular ultra- 
sound obtained after analyzing 10 random sites has been 
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utilized in an effort to better quantitate intimal proliferation 
because the routine three-site image analysis has been found to be 
somewhat less accurate in assessing heterogeneous disease (40). 
Conclusions. The development of myointimal hyperplasia, 
detected accurately by intravascular ultrasound in heart trans- 
plant recipients, is influenced by the interdependence of donor 
age, lipids (serum triglycerides) and allograft rejection. The 
present study establishes an accurate and clinically useful 
predictive model that can be applied to individual heart 
transplant recipients to assess their risk for developing severe 
intimal proliferation and, thereby, cardiac allograft vasculopa- 
thy. Furthermore, this model enables the clinician to identify 
those heart transplant recipients at high risk for a cardiac event 
in whom closer monitoring for rejection and risk factor mod- 
ification may be warranted. 
We appreciate the editorial assistance of Jeanette Cothren. 
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